Galaxy Group Investments’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Galaxy Group Investments’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.04M	Buy	+8,500	New	+$975K	0.12%	36

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Galaxy Group Investments's XBI Position: Q4 2025 in Review

Galaxy Group Investments opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q4 2025: 8,500 shares worth $1.04M. The stake represents 0.12% of the portfolio and ranks #36 among its holdings.

814 funds tracked by Wall St. Rank hold XBI as of Q4 2025.

Galaxy Group Investments held 8,500 shares of State Street SPDR S&P Biotech ETF worth $1.04M as of Q4 2025.
State Street SPDR S&P Biotech ETF was a new Galaxy Group Investments position in Q4 2025.
State Street SPDR S&P Biotech ETF made up 0.12% of Galaxy Group Investments's portfolio in Q4 2025, its #36 holding.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2025.

Based on Galaxy Group Investments's 13F filing for Q4 2025, filed 18 Feb 2026.